An observational study in Metastatic Prostate Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in China. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Prostatic Neoplasms by Novartis — 13 open to participants now, 25 under way, 4 of them phase 3. Prostatic Neoplasms · Novartis.
Among the 82 studies in Prostatic Neoplasms by Novartis, this one is one of 6 that started in 2026, is one of 9 observational ones, reaches primary completion later than 18 of the 24 other live ones, and was the 75th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →13 of the 82 studies in Prostatic Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Men only
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 5 more countries
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Canada, Czechia and 8 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 11 more countries
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 99 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 26 · Phase 3 14 · Phase 4 14
First in 1999; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 72 across the 70 interventional studies, 753 across the 9 observational. Of the 54 that completed or were terminated, 11 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
7 of the studies in Prostatic Neoplasms by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07928037Novartis PharmaceuticalsA Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic Castration Resistant Prostate Cancer Patients | 2026-11-25 |
| NCT06991556Novartis PharmaceuticalsAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | 2026-12-03 |
| NCT05849298Novartis PharmaceuticalsA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | 2026-12-23 |
| NCT04597411EndocyteStudy of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | 2027-01-01 |
| NCT07174063Novartis PharmaceuticalsA Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer | 2027-01-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 82 studies in Prostatic Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical outcomes, real-world characteristics, and quality of life during the treatment period and up to one year after treatment completion.
The study population will be divided into two cohorts, enrolling patients with mCRPC and mHSPC, respectively. Patients planned to receive lutetium (177Lu) vipivotide tetraxetan treatment according to treating physician's assessment will be enrolled in the study upon signing an informed consent form. Patients must meet all inclusion criteria defined in the protocol and not meet any exclusion criteria. The patients' medical history, prostate cancer disease characteristics, demographics, and baseline data will be collected through medical records and examination reports. Treatment patterns, treatment outcomes, and HRQoL data will be collected during study follow-up visits through patient records, examination reports, and self-reported data. This study does not have a control group; instead, a self-control method will be used, with the patients' baseline data before the start of treatment serving as the control for efficacy, safety, and HRQoL assessments. The index date for this study is defined as the date of the first administration of lutetium (177Lu) vipivotide tetraxetan
The study population will be recruited from approximately 25 research centers in China
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult male patients diagnosed with mCRPC or mHSPC Initiating lutetium (177Lu) vipivotide tetraxetan treatment by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of cycle 1 Written ICF must be obtained prior to any data collection Participants must have adequate organ function following Society of Nuclear Medicine and Molecular Imaging (SNMMI) consensus (Hope et al., 2023)
Exclusion Criteria:
Simultaneous participation in any trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan during the study period
Other protocol-defined inclusion / exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with Metastatic Castration-Resistant Prostate Cancer (mCRPC) previously treated with at least one ARPI with or without taxane regimens.
Patients diagnosed with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
prostate-specific antigen (PSA) 50 response rate
Defined as the proportion of patients with a confirmed decrease in PSA levels by ≥50% from baseline
Time frame: from 1 month before the index date through to 1 year after the end-of-treatment (EOT) visit
prostate-specific antigen (PSA) 90 response rate
Defined as the proportion of patients with confirmed decreases in PSA level by ≥90% from baseline
Time frame: from 1 month before the index date through to 1 year after the end-of-treatment (EOT) visit
Progression-Free Survival (PFS)
Defined as the time from the index date to the first occurrence of PSA progression or radiographic progression according to the Prostate Cancer Working Group 3 criteria, clinical progression assessed by the investigator, or death due to any cause (whichever occurs first)
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Radiographic progression-free survival (rPFS)
Defined as the time from the index date to the first occurrence of radiographic progression according to the PCWG3 criteria or death due to any cause (whichever occurs first)
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Clinical PFS
Defined as the time from the index date to the first occurrence of clinical progression assessed by the investigator or death due to any cause (whichever occurs first). Clinical progression is determined by the investigator and may be based on the following criteria: 1) Significant increase in tumor pain requiring initiation of another systemic anti-cancer treatment regimen; 2) The need to immediately start new anti-cancer treatment, surgery, or radiotherapy intervention due to complications caused by tumor progression, even in the absence of radiographic progression; 3) Deterioration of Eastern Cooperative Oncology Group (ECOG) performance status to ≥ 3, and the investigator determines that the deterioration indicates clinical progression
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Time to PSA progression
Defined as the time from the index date to the first occurrence of PSA progression or death due to any cause. According to the PCWG3 criteria, PSA progression is defined as follows: 1. For patients whose PSA has declined from baseline: PSA increased by ≥25% compared with the lowest value and the absolute value was ≥2 ng/mL, and was re-evaluated and confirmed after ≥3 weeks. 2. For patients whose PSA has not declined from baseline: After at least 12 weeks of treatment with the study drug, the PSA level increased by ≥25% from the baseline and the absolute value was ≥2 ng/mL
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Second Progression-Free Survival (PFS2)
Defined as the time from the initiation of the first subsequent systemic anti-tumor therapy following the end of treatment with lutetium (177Lu) vipivotide tetraxetan to the first occurrence of radiographic progression or PSA progression according to the PCWG3 criteria, clinical progression as assessed by the investigator, or death due to any cause (whichever occurs first)
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
OS
Defined as the time from the index date to death due to any cause
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Time to a first symptomatic skeletal event (SSE)
Defined as the time from the index date to the first occurrence of an SSE. SSEs include the use of external beam radiation therapy to prevent or palliate skeletal symptoms, the occurrence of a new symptomatic pathological fracture (vertebral or non-vertebral), the occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention (whichever occurs first)
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Time to first subsequent therapy
Defined as the time from the index date to the start date of the first subsequent therapy for prostate cancer. Subsequent therapy refers to systemic anti-tumor treatment initiated after the patient discontinues lutetium (177Lu) vipivotide tetraxetan treatment
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Disease control rate (DCR)
Defined as the proportion of patients with complete response (CR) / partial response (PR), and stable disease (SD) as the best response in soft tissue lesion evaluation
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Objective response rate (ORR)
Defined as the proportion of patients with CR and PR as the best response in soft tissue lesion evaluation assessed referring to the evaluation criteria
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Time to response (TTR)
Defined as the time from the index date to the first documentation of CR or PR for soft tissue lesions referring to the evaluation criteria
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Duration of response (DoR)
Defined as the time from the first documentation of objective response (CR or PR) to the first occurrence of disease progression (radiographic, clinical, or PSA progression) or death due to any cause (whichever occurs first)
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Time to soft tissue progression (TTSTP)
Defined as the time from the index date to the occurrence of soft tissue progression referring to the evaluation criteria or death due to any cause (whichever occurs first)
Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit
Number of participants by treatment dose and cycles of lutetium (177Lu) vipivotide tetraxetan
Number of participants by treatment dose and cycles of lutetium (177Lu) vipivotide tetraxetan
Time frame: Data collection of previous treatments for prostate cancer: from the time of prostate cancer diagnosis to the index date / Data collection of subsequent treatments for prostate cancer: from the index date to 1 year after the EOT visit
Number of participants by treatment sequences for prostate cancer
Prior treatment lines and subsequent treatments (including: ARPI, ADT, chemotherapy, radical prostatectomy, radiological treatment etc.)
Time frame: Data collection of previous treatments for prostate cancer: from the time of prostate cancer diagnosis to the index date / Data collection of subsequent treatments for prostate cancer: from the index date to 1 year after the EOT visit
Patient demographics and baseline characteristics
Time frame: From 1 month before the index date to the index date
Prostate cancer disease characteristics: Number of patients with Previous prostate cancer history
Time frame: Baseline
Prostate cancer disease characteristics: Gleason score
Typical Gleason Scores range from 6-10. The higher the Gleason Score, the more likely that the cancer will grow and spread quickly.
Time frame: From 1 month before the index date to the index date
Prostate cancer disease characteristics: Number of patients by metastasis status
Time frame: From 1 month before the index date to the index date
Prostate cancer disease characteristics: Number of patients by prostate cancer-related genetic mutation status
Time frame: From 1 month before the index date to the index date
Prostate cancer disease characteristics: Baseline prostate-specific antigen (PSA) level
Time frame: Baseline
Prostate cancer disease characteristics: prostate-specific antigen (PSA) doubling time
Time frame: From 1 month before the index date to the index date
Prostate cancer disease characteristics: Prostate-Specific Membrane Antigen (PSMA) diagnostic drug usage
Time frame: From 1 month before the index date to the index date
Prostate cancer disease characteristics: Baseline PET-CT results
Time frame: Baseline
Prostate cancer disease characteristics: Baseline testosterone level
Time frame: Baseline
Prostate cancer disease characteristics: Baseline Eastern Cooperative Oncology Group (ECOG) performance status
ECOG performance status is measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.
Time frame: Baseline
Prostate cancer disease characteristics: Number of patients with family history of prostate cancer
Time frame: Baseline
Prostate cancer disease characteristics: Number of patients with carcinoembryonic Antigen (CEA)
Time frame: From 1 month before the index date to the index date
Adverse events
Time frame: From the index date to 1 year after the EOT visit
FACT-P score
The FACT-P was developed to measure the health-related quality of life (HRQOL) in patients diagnosed with prostate cancer. It extends the general FACT-G scale, which assesses cancer patients' overall quality of life, by adding specific items related to prostate cancer therapy. The FACT-P consists of two main sections: 1. FACT-G: A general section that covers four domains: Physical Well-Being (PWB),Social/Family Well-Being (SWB),Emotional Well-Being (EWB),Functional Well-Being (FWB) 2. Prostate Cancer Specific Section: Focuses on issues unique to prostate cancer patients, such as urinary symptoms, sexual health, and the side effects of treatment. The scoring system for the FACT-P uses a 5-point Likert scale (from 0 to 4,from good to bad). Scores are calculated across different domains and subscales, and the total score is calculated by summing the scores across all domains, providing a range of 0 to 156. A high FACT-P score indicates a worse outcome.
Time frame: From 1 month before the index date to 1 year after the EOT visit
BPI-SF score
Brief Pain Inventory-Short Form (BPI-SF). The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. BPI assessment areas including severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week. No scoring algorithm, but "worst pain" or the arithmetic mean of the four severity items can be used as measures of pain severity; the arithmetic mean of the seven interference items can be used as a measure of pain interference.
Time frame: From 1 month before the index date to 1 year after the EOT visit
EQ-5D-5L questionnaire score
EuroQol 5-Dimension 5-Level (EQ-5D-5L). The 5-level EQ-5D version (EQ-5D-5L) descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Time frame: From 1 month before the index date to 1 year after the EOT visit
FACT-RNT score
Functional Assessment of Cancer Therapy - Radionuclide Therapy (FACT-RNT). The FACT-RNT was designed for use and future adaptation with a broad variety of RNT agents with different molecular targeting mechanisms and radioisotopes. The FACT-RNT, a 15-item measure of symptoms/toxicities with higher total scores(range:0-60) indicating less symptom burden.
Time frame: From 1 month before the index date to 1 year after the EOT visit
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Aug 2029, 42 months after the start.
Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 42 months is close to that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.